NCT00799877

Chronic Plaque Psoriasis (Ps) Registry

Brief summary

The purpose of this study is to evaluate the long-term safety of an Active Drug in Adult Patients with Chronic Plaque Psoriasis (Ps).

Observational study

Status:
Completed
Conditions:
Chronic Plaque Psoriasis
Enrollment:
6065 patients
Protocol ID:
P10-023
Observational model:
Cohort
Time perspective:
Prospective

 

Eligibility criteria

Participant attributes:
Male and Female

Age:

From 18 Years to 99 Years.

Inclusion Criteria:

1. An adult patient (18 years of age or older) with chronic plaque psoriasis who has been
prescribed HUMIRA® therapy according to the local product labeling and meets one of
the following criteria:

- New initiated (within 4 weeks of registry entry) on HUMIRA® therapy;

- Initiated HUMIRA® therapy in the past and:

- Has received continuous (no more than 70 consecutive days off drug) HUMIRA®
therapy and the physician can provide source documentation of SAEs, AEs, of
Special Interest, and dosing information since initiation of therapy.

OR

- Is entering after participation in an AbbVie HUMIRA (adalimumab) sponsored study
and has received continuous (no more than 70 consecutive days off drug) HUMIRA®
therapy after the completion of AbbVie sponsored study and physician can provide
source documentation of SAEs, AEs of Special Interest, and dosing information
since initiation of commercial HUMIRA® (defined as a prescribed/non study drug).

2. Patient is willing to consent to data being collected and provided to AbbVie;

3. Patient is capable of and willing to give written informed consent and to comply with
the requirements of the registry.

Exclusion Criteria:

- Patient should not be enrolled if he/she cannot be treated in accordance with the local
product label.

All the cities where the clinical studies are located

Calgary - T2G 1B1
Edmonton - T5K 1X3
Surrey - V3R 6A7
Surrey - V3V 0C6
Vancouver - V5Z 3N9
St. John's - A1A 4Y3
St. John's - A1B 4S8
St. John's - A1B 5E8
St. John's - A1C 2H5
Halifax - B3K 5R3
Hamilton - L8N 1Y2
London - N6A 3H7
Markham - L3P 1X2
Newmarket - L3Y 6P5
Niagara Falls - L2E 2R4
North Bay - P1B 3Z7
Peterborough - K9J 5K2
Toronto - M5S 1B2
Waterloo - N2J 1C4
Windsor - N8W 1E6
Drummondville - J2B 5L4
Montréal - H2X 2V1
Quebec City - G1J 1X7
Québec - G1V 4X7
Quebec City - G1J 1X7
Westmount - H3Z 2S6
Moncton - E1C 2Z3
Winnipeg - R3C 0N2

More information about this study

clinicaltrials.gov